The myths of parallel trade in medicines
Parallel trade in medicines brings direct savings for the destination country, as well as an important element of price competition to patented medicines. Attempts by manufacturers to stifle parallel trade are usually illegal, as well as counter-productive. Two current examples supply quota systems...
Gespeichert in:
| Veröffentlicht in: | Consumer Policy Review 2004-01, Vol.14 (1), p.13 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 13 |
| container_title | Consumer Policy Review |
| container_volume | 14 |
| creator | Macarthur, Donald |
| description | Parallel trade in medicines brings direct savings for the destination country, as well as an important element of price competition to patented medicines. Attempts by manufacturers to stifle parallel trade are usually illegal, as well as counter-productive. Two current examples supply quota systems and free pricing with rebates - are described. This article develops themes that were raised in an earlier article 'Parallel trading of medicines: the case for a fair deal' (Consumer Policy Review 2001; 11:6-10). [PUBLICATION ABSTRACT] |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_reports_219247553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>546205321</sourcerecordid><originalsourceid>FETCH-LOGICAL-p848-79ffd0e89d74e580c685d19453e65bb7a4f78939cace7f4a7a6a2de202fe62fd3</originalsourceid><addsrcrecordid>eNotzrkKwkAUQNEpFFz_YexsArMvpYgbCDbp5Zl5g5Fo4kws_HsFrW53uAMyZt7wgnOpRmSS840xwT2zY7Isr0jv7_6aaRtpBwmaBhvaJwhI6we9Y6ir-oF5RoYRmozzf6ek3G7K9b44nnaH9epYdE65wvoYA0Png1WoHauM04F7pSUafblYUNE6L30FFdqowIIBEVAwEdGIGOSULH5sl9rnC3N_Tti1qc_n77BQVmspPwz_Ors</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219247553</pqid></control><display><type>article</type><title>The myths of parallel trade in medicines</title><source>Business Source Complete</source><creator>Macarthur, Donald</creator><creatorcontrib>Macarthur, Donald</creatorcontrib><description>Parallel trade in medicines brings direct savings for the destination country, as well as an important element of price competition to patented medicines. Attempts by manufacturers to stifle parallel trade are usually illegal, as well as counter-productive. Two current examples supply quota systems and free pricing with rebates - are described. This article develops themes that were raised in an earlier article 'Parallel trading of medicines: the case for a fair deal' (Consumer Policy Review 2001; 11:6-10). [PUBLICATION ABSTRACT]</description><identifier>ISSN: 0961-1134</identifier><language>eng</language><publisher>London: Association for Consumers Research</publisher><subject>Competition ; Cost control ; Free trade ; Health care policy ; Health insurance ; International law ; International trade ; Manufacturers ; Patients ; Pharmaceutical industry ; Prescription drugs ; Pricing policies ; Reimbursement ; Statistical data ; Wholesalers</subject><ispartof>Consumer Policy Review, 2004-01, Vol.14 (1), p.13</ispartof><rights>Copyright Association for Consumers Research Jan/Feb 2004</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>312,778,782,789</link.rule.ids></links><search><creatorcontrib>Macarthur, Donald</creatorcontrib><title>The myths of parallel trade in medicines</title><title>Consumer Policy Review</title><description>Parallel trade in medicines brings direct savings for the destination country, as well as an important element of price competition to patented medicines. Attempts by manufacturers to stifle parallel trade are usually illegal, as well as counter-productive. Two current examples supply quota systems and free pricing with rebates - are described. This article develops themes that were raised in an earlier article 'Parallel trading of medicines: the case for a fair deal' (Consumer Policy Review 2001; 11:6-10). [PUBLICATION ABSTRACT]</description><subject>Competition</subject><subject>Cost control</subject><subject>Free trade</subject><subject>Health care policy</subject><subject>Health insurance</subject><subject>International law</subject><subject>International trade</subject><subject>Manufacturers</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Prescription drugs</subject><subject>Pricing policies</subject><subject>Reimbursement</subject><subject>Statistical data</subject><subject>Wholesalers</subject><issn>0961-1134</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNotzrkKwkAUQNEpFFz_YexsArMvpYgbCDbp5Zl5g5Fo4kws_HsFrW53uAMyZt7wgnOpRmSS840xwT2zY7Isr0jv7_6aaRtpBwmaBhvaJwhI6we9Y6ir-oF5RoYRmozzf6ek3G7K9b44nnaH9epYdE65wvoYA0Png1WoHauM04F7pSUafblYUNE6L30FFdqowIIBEVAwEdGIGOSULH5sl9rnC3N_Tti1qc_n77BQVmspPwz_Ors</recordid><startdate>20040101</startdate><enddate>20040101</enddate><creator>Macarthur, Donald</creator><general>Association for Consumers Research</general><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>7WY</scope><scope>7WZ</scope><scope>7XB</scope><scope>87Z</scope><scope>8AO</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>F~G</scope><scope>K60</scope><scope>K6~</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYYUZ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20040101</creationdate><title>The myths of parallel trade in medicines</title><author>Macarthur, Donald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p848-79ffd0e89d74e580c685d19453e65bb7a4f78939cace7f4a7a6a2de202fe62fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Competition</topic><topic>Cost control</topic><topic>Free trade</topic><topic>Health care policy</topic><topic>Health insurance</topic><topic>International law</topic><topic>International trade</topic><topic>Manufacturers</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Prescription drugs</topic><topic>Pricing policies</topic><topic>Reimbursement</topic><topic>Statistical data</topic><topic>Wholesalers</topic><toplevel>online_resources</toplevel><creatorcontrib>Macarthur, Donald</creatorcontrib><collection>Global News & ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM Global</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ABI/INFORM Collection China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Consumer Policy Review</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Macarthur, Donald</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The myths of parallel trade in medicines</atitle><jtitle>Consumer Policy Review</jtitle><date>2004-01-01</date><risdate>2004</risdate><volume>14</volume><issue>1</issue><spage>13</spage><pages>13-</pages><issn>0961-1134</issn><abstract>Parallel trade in medicines brings direct savings for the destination country, as well as an important element of price competition to patented medicines. Attempts by manufacturers to stifle parallel trade are usually illegal, as well as counter-productive. Two current examples supply quota systems and free pricing with rebates - are described. This article develops themes that were raised in an earlier article 'Parallel trading of medicines: the case for a fair deal' (Consumer Policy Review 2001; 11:6-10). [PUBLICATION ABSTRACT]</abstract><cop>London</cop><pub>Association for Consumers Research</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-1134 |
| ispartof | Consumer Policy Review, 2004-01, Vol.14 (1), p.13 |
| issn | 0961-1134 |
| language | eng |
| recordid | cdi_proquest_reports_219247553 |
| source | Business Source Complete |
| subjects | Competition Cost control Free trade Health care policy Health insurance International law International trade Manufacturers Patients Pharmaceutical industry Prescription drugs Pricing policies Reimbursement Statistical data Wholesalers |
| title | The myths of parallel trade in medicines |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T20%3A22%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20myths%20of%20parallel%20trade%20in%20medicines&rft.jtitle=Consumer%20Policy%20Review&rft.au=Macarthur,%20Donald&rft.date=2004-01-01&rft.volume=14&rft.issue=1&rft.spage=13&rft.pages=13-&rft.issn=0961-1134&rft_id=info:doi/&rft_dat=%3Cproquest%3E546205321%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219247553&rft_id=info:pmid/&rfr_iscdi=true |